You must subscribe to access archives older
than one year.
Take a free trial of Briefing In Play® now.
Subscribe Here
TERMS OF USE

The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.

Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for use by individuals, as long as the feeds are used for such individual’s personal, non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You are required to use the RSS feeds as provided by Briefing.com and you may not edit or modify the text, content or links supplied by Briefing.com. To acquire more extensive licensing rights to Briefing.com content please review this page.

Link to Content Pages:
The RSS service may be used only with those platforms from which a functional link is made available that, when accessed, takes the viewer directly to the display of the full article on the Briefing.com web site. You may not display the RSS content in a manner that does not permit successful linking to, redirection to or delivery of the applicable Briefing.com web site page. You may not insert any intermediate page, “splash” page or any other content between the RSS link and the applicable Briefing.com web site page.

Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS content, and any and all Briefing.com logos and trademarks used in connection with the RSS service. You are required to provide appropriate attribution to the Briefing.com web site in connection with your use of the RSS feeds. If you provide this attribution using a graphic we require you to use the Briefing.com web site logo that we have incorporated into the Briefing.com RSS feed.

Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any or all of the RSS feeds at any time and to require you to cease displaying, distributing or otherwise using any or all of the RSS feeds for any reason including, without limitation, your violation of any provision of these Terms of Use or the terms and conditions of the Briefing.com Reader Agreement. Briefing.com assumes no liability for any of your activities in connection with the RSS feeds or for your use of the RSS feeds in connection with your web site.

Briefing.com
Subscribers Log In
 
  • HOME
  • OUR VIEW
    • Page One
    • The Big Picture
    • Ahead of the Curve
  • ANALYSIS
    • Premium Analysis
    • Story Stocks
  • MARKETS
    • Stock Market Update
    • Bond Market Update
    • Market Internals
    • After Hours Report
    • Weekly Wrap
  • CALENDARS
    • Upgrades/Downgrades
    • Economic
    • Stock Splits
    • IPO
    • Earnings
    • Conference Calls
    • Earnings Guidance
  • EMAILS
    • Edit My Profile
  • LEARNING CENTER
    • About Briefing.com
    • Ask An Analyst
    • Analysis
    • General Concepts
    • Strategies
    • Resources
    • Video
  • COMMUNITY
    • Twitter
    • Facebook
    • LinkedIn
    • YouTube
    • RSS
  • SEARCH
Login | Archive | EmailEmail |
HOME > Analysis >Story Stocks >The Healthcare sector...
Story Stocks® Archive
Last Update: 11-Jul-12 11:12 ET
The Healthcare sector (-0.08%) is trading down slightly today, underperforming the S&P 500

General Commentary: Lightly traded and very cheaply priced Hemispherx Biopharma (HEB) is up sharply today on news that it has reached an agreement with the FDA on the filing requirements for the company's Complete Response in support of its Ampligen New Drug Application for the treatment of chronic fatigue syndrome. The FDA has accepted for review new analyses of data from HEB's AMP-516 Phase 3 clinical trial. Previously, the FDA had recommended at least one additional clinical study including at least 300 patients on dose regimens intended for marketing. Hemispherx frequently sees volatility around any rumors of avian flu due to its product Alferon LDO, which is currently in voluntary clinical trials as a potential treatment.

Gainers on news: Hemispherx Biopharma (HEB +26.8%) FDA agreed to accept for review new analyses of data from the AMP-516 Phase 3 clinical trial in support of its Ampligen NDA Tengion (TNGN +8.87%) Announced continued clinical progress on key milestones for the ongoing Phase 1 trial of its most advanced product candidate, the Neo-Urinary Conduit Orexigen Therapeutics (OREX +4.68%) Announced that The Light Study, the cardiovascular outcomes clinical trial for Contrave, is enrolling faster than originally projected; interim analysis now expected in 2013 Q1Decliners on news: Gilead Sciences (GILD -2.57%) Competitor GlaxoSmithKline (GSK) announced its investigational integrase inhibitor dolutegravir for the treatment of HIV was superior than GILD's Atripla in a Phase 3 trial. Gainers on earnings: No notable gainers on earnings Decliners on earnings: No notable decliners on earnings

Upgrades/Downgrades: Vision-Sciences (VSCI +5.34%) Initiated with a Buy at Lazard, target $3 Mead Johnson Nutrition (MJN +2.02%) Added to Current Better Values List at William Blair HMS Holdings (HMSY -2.63%) Downgraded to Hold from Buy at Jefferies

General Commentary: Lightly traded and very cheaply priced Hemispherx Biopharma (HEB) is up sharply today on news that it has reached an agreement
 
Add this to my Page Alerts.
MARKET PLACE
SPONSORED LINKS
 
  Follow Us On Linkedin  
 
 
LOGIN

CONTACT US
Support
Sitemap
PREMIUM SERVICES
Take a Tour
Compare Services
Custom Tickers
INSTITUTIONAL SALES
ADVERTISING

CONTENT LICENSING

EMAILS & NEWSLETTERS
ABOUT US
Our Experts
Management Team

COMMUNITY
MEDIA
Events
News
Awards
PRIVACY STATEMENT
Reader Agreement
Policies
Disclaimer
Copyright © Briefing.com, Inc. All rights reserved.
Close
You must log in or register to access this area.
Tip of the Day
Virtual Url Page Popup